Apricus Biosciences Inc (NASDAQ:APRI) was the recipient of a large decrease in short interest in the month of September. As of September 28th, there was short interest totalling 1,041,203 shares, a decrease of 29.4% from the September 14th total of 1,474,242 shares. Based on an average daily volume of 426,171 shares, the short-interest ratio is presently 2.4 days. Currently, 4.6% of the company’s stock are sold short.
Shares of APRI opened at $0.29 on Friday. Apricus Biosciences has a fifty-two week low of $0.25 and a fifty-two week high of $3.34. The company has a market capitalization of $7.27 million, a PE ratio of -0.29 and a beta of 1.22.
Apricus Biosciences (NASDAQ:APRI) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. As a group, research analysts expect that Apricus Biosciences will post -0.4 earnings per share for the current fiscal year.
Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.
Featured Story: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.